{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifyqdbmzgcqfw6oxq3m2xptoybfzfrdffm6vl452h7xjvtincjee4",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mfmpznan6ux2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicijmrgxvsy5d4ruyyyi7xaksysdoq4lfpuonvo3irtygagnfa5i4"
    },
    "mimeType": "image/jpeg",
    "size": 69828
  },
  "path": "/2026/02/23/him-hers-earnings-2026-outlook-compounded-semaglutide/?utm_campaign=rss",
  "publishedAt": "2026-02-24T01:14:06.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Health tech",
    "biotechnology",
    "drug development",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line.",
  "title": "STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding",
  "updatedAt": "2026-02-24T01:37:58.000Z"
}